Preferred Name |
haloperidol |
|
Synonyms |
R-1625 |
|
Definitions |
A phenylbutylpiperadine derivative with antipsychotic, neuroleptic, and antiemetic activities. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. Antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C537" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C537" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039474 |
|
altLabel |
R-1625 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone Haldol McN-JR-1625 |
|
CAS Registry |
52-86-8 |
|
cui |
C0591585 C0700677 C0018546 C0699382 |
|
Date last modified |
2008-02-13 |
|
definition |
A phenylbutylpiperadine derivative with antipsychotic, neuroleptic, and antiemetic activities. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. Antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C537" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C537" NCI Thesaurus) |
|
Legacy PDQ ID |
2108 |
|
LT |
TRD |
|
NCI ID |
C537 |
|
notation |
CDR0000039474 |
|
NSC Code |
170973 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
haloperidol |
|
tui |
T109 T121 |